Hebei Changshan Biochemical Pharmaceutical announcement, the company's stock has deviated by more than 30% from the closing price for three consecutive trading days, indicating abnormal fluctuations in stock trading. The company is paying attention and verifying that there are no corrections or supplements needed to the previously disclosed information; no significant undisclosed information that may have a significant impact on the company's stock trading price has been reported in the recent public media; the recent operational situation is normal, the main business has not changed, and there have been no significant changes in the internal and external operating environment. The ebenaideptide injection by the company has not been launched for sale, the drug's marketing authorization application has been accepted by the National Medical Products Administration, currently in the professional evaluation stage, and there is still uncertainty about whether it will be approved for market launch and the approval time. The revenue in the first half of 2024 was 0.568 billion yuan, a decrease of 30.79% compared to the same period last year; the net profit attributable to the shareholders of the listed company was a loss of 46.9027 million yuan.